PD-1/PD-L1抗体阻断药物的研究进展与临床应用
- 分享到:
摘要:
研究发现在生理状况下PD-1与PD-L1相互识别能产生负向信号,该信号通路一旦被激活后,可诱导抗原特异性效应T细胞凋亡,该生理效应可防止过度免疫反应带来的附加损伤,因此该信号通路又被形象的称为“免疫刹车”.如果利用特异性阻断剂阻断PD-1/PD-L1信号通路,便可以恢复免疫细胞的杀伤抑制功能.截止至2019年12月,全球已有7种PD-1阻断药物和3种PD-L1阻断药物批准上市,均属于大分子抗体类药物,其中的4种PD-1单抗由我国自主研发,目前中国大陆批准上市的PD-1/PD-L1阻断药物有8种.这些单抗药物在多种肿瘤的临床治疗中产生较好的疗效,并且部分患者得到完全缓解,具有良好的应用前景.从其生物学背景出发,按药物分类综述了近年来PD-1/PD-L1信号通路抑制剂在临床治疗中的应用和表现,讨论了目前此类药物在临床使用中存在的问题以及应对策略.
Many studies have found that the mutual recognition of PD-1 and PD-L1 could produce negative signals under physiological conditions.Once the signaling pathway was activated,and the signaling pathway could induce the apoptosis of antigen-specific effect T cells.Then the physiological effect could prevent additional damages which caused by excessive immune response.Therefore,the signaling pathway is named as theimmune brake.If the PD-1/PD-L1 signaling pathway was blocked by a specific blocker,the killing inhibitory function of immune cells would be restored.Up to the December of 2019,seven PD-1 blocking drugs and three PD-L1 blocking drugs have been approved for marketing worldwide,all of which belonging to macromolecular antibody drugs.Among them,four PD-1 monoclonal antibodies were independently developed in China.Currently,eight PD-1/PD-L1 blocking drugs have been approved for marketing in China's Mainland.These monoclonal antibodies have produced good efficacy in the clinical treatment of different tumors.A few patients have achieved complete remission,forecasting a good application prospect for these antibodies.Based on its biological background,we reviewed the application and performance of PD-1/PD-L1 signaling pathway inhibitors in clinical treatment in recent years according to drug classification,and discussed the existing problems in clinical use of such drugs and corresponding strategies.
作者:
王选年 史烨萍 岳锋
Wang Xuannian;Shi Yeping;Yue Feng(College of Life Sciences,Henan Normal University,Xinxiang,453007,China;Biotechnology Research Center,Xinxiang University,Xinxiang,453003,China)
机构地区:
betway官方app 生命科学学院 新乡学院生物技术研究中心
出处:
《betway官方app 学报：自然科学版》 CAS 北大核心 2021年第2期87-92,共6页
基金:
国家自然科学基金青年科学基金(31702216)。
关键词:
抗肿瘤 PD-1/PD-L1 信号通路 临床应用 抗体药物
anti-tumor PD-1/PD-L1 signal path clinical application antibody drug
分类号:
Q819 [生物学—生物工程] R979.1 [医药卫生—药品]
